Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study

Background: Combined therapy of continuous low dose capecitabine and high dose celecoxib targeting angiogenesis was used in a phase II trial to treat advanced cancer patients. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used to monitor antiangiogenic effects. Material and Methods: 37 Patients (21 men, 16 women), mean age 60 years, with advanced and progressive cancer of various tumor types were included. Therapy consisted of 2 × 500 mg oral capecitabine/ day and 2 × 400 mg oral celecoxib/day continuously until progression of disease. To monitor antiangiogenic effects, DCE-MRI measurements were performed at baseline, after 1 month, and after 3 months of therapy. Tumor assessment was performed according to RECIST criteria, toxicity was evaluated according to the CTC version 2.0 catalogue. Results: Therapy was well tolerated without grade 3 and 4 toxicities. The mean number of treatment cycles was 4 (range: 1-15+). Disease stabilization after 3 cycles was seen in 11 patients. 6 patients were stable over long periods. The mean number of treatment cycles in this group was 10 (range: 7-15+). DCE-MRI demonstrated a reduction of tumor vessel permeability and blood flow in patients who reached stable disease or some minor regression. Conclusion: Continuous dosing of the combination of capecitabine and celecoxib was well tolerated, produced antiangiogenic effects, and has antitumor activity. Patients with rapid progression did not benefit. Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients - Results of a Phase II Study Simone Steinbild Jann Arends Michael Medinger Brigitte Häring Annette Frost Joachim Drevs Clemens Unger Ralph Strecker Jürgen Hennig Klaus Mross Tumor Biology Center at the Albert Ludwigs University Freiburg and MR Development and Application Center of the University Hospital Freiburg, Germany

[1]  Susan M. Kilroy,et al.  PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. , 2002, The Journal of clinical investigation.

[2]  D. Ribatti,et al.  Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine , 1999 .

[3]  R. Kaufmann,et al.  Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study , 2003, Cancer Chemotherapy and Pharmacology.

[4]  G. Gasparini,et al.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? , 2003, The Lancet. Oncology.

[5]  H. Ishitsuka.  Capecitabine: Preclinical Pharmacology Studies , 2000, Investigational New Drugs.

[6]  M. Cumming,et al.  Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.

[7]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  I. Voutsadakis.  Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox-2 , 2007, Journal of cellular and molecular medicine.

[9]  Jürgen Hennig,et al.  Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. , 2005, European journal of cancer.

[10]  R. Kerbel,et al.  'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. , 2000, European journal of cancer.

[11]  J. Drevs,et al.  Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. , 2004, Anticancer research.

[12]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[14]  D. G. Wenzel,et al.  A model system for measuring comparative toxicities of cardiotoxic drugs for cultured rat heart myocytes, endothelial cells and fibroblasts. II. Doxorubicin, 5-fluorouracil and cyclophosphamide. , 1984, Toxicology.

[15]  M. Landthaler,et al.  Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors , 2003, Cancer.

[16]  Albrecht Reichle,et al.  Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. , 2004, Archives of dermatology.

[17]  L. Ellis,et al.  Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts , 2004, Cancer biology & therapy.

[18]  G. Avvisati,et al.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  D. Ribatti,et al.  Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. , 1999, Cancer research.

[20]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[21]  Kristian Pietras,et al.  A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Baruchel,et al.  Low-Dose Metronomic Chemotherapy: Myth or Truth? , 2006, Oncology Research and Treatment.

[23]  J. Štěrba,et al.  Combined Biodifferentiating and Antiangiogenic Oral Metronomic Therapy is Feasible and Effective in Relapsed Solid Tumors in Children: Single-Center Pilot Study , 2006, Oncology Research and Treatment.

[24]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[25]  M. Toi,et al.  Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. , 2005, The Lancet. Oncology.

[26]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[27]  M. Guzmán,et al.  Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas , 2004, Cancer Research.

[28]  D. Yankelevitz,et al.  Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Cohen,et al.  Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  K. Scheffler,et al.  DCE-MRI in clinical trials: data acquisition techniques and analysis methods. , 2003, International journal of clinical pharmacology and therapeutics.

[31]  S. Rafii,et al.  Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. , 2000, Blood.

[32]  C. Xiaoguang.  Antineoplastic effects of peroxisome proliferator activated receptorγ agonists , 2005 .

[33]  A. Barqawi,et al.  Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma , 2003, Cancer.

[34]  K. Mross.  Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[35]  J. Drevs,et al.  Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Cosimo,et al.  Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma , 2004, Cancer.

[37]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[38]  Zhen-ping Zhu,et al.  Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. , 2005, Frontiers in bioscience : a journal and virtual library.

[39]  Henk-Jan Guchelaar,et al.  Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. , 2004, Cancer treatment reviews.

[40]  T. Vogt,et al.  Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far‐advanced melanoma and soft tissue sarcoma , 2004, Cancer.

[41]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[42]  Robert M Elashoff,et al.  A Phase I Trial to Determine the Optimal Biological Dose of Celecoxib when Combined with Erlotinib in Advanced Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[43]  E. D. de Vries,et al.  Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. , 2004, Cancer treatment reviews.

[44]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[45]  J. Masferrer,et al.  Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.

[46]  S. Baruchel,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.

[47]  S. Fox,et al.  Thymidine phosphorylase is angiogenic and promotes tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Levine,et al.  Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. , 2002, Cancer research.

[49]  U. Gehling,et al.  Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. , 2004, Experimental cell research.